Bayer Aktiengesellschaft (BAYZF)
| Market Cap | 56.74B +78.1% |
| Revenue (ttm) | 51.84B -1.7% |
| Net Income | -1.99B |
| EPS | -2.02 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 10.85 |
| Dividend | 0.13 (0.23%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 2,600 |
| Open | 56.94 |
| Previous Close | 56.27 |
| Day's Range | 56.66 - 56.94 |
| 52-Week Range | 30.00 - 61.38 |
| Beta | 0.83 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Bayer announces FDA accepts Lynkuet sNDA for Priority Review
Bayer (BAYRY) announced that the U.S. Food and Drug Administration has accepted the company’s supplemental New Drug Application and granted Priority Review designation for Lynkuet under investigation ...
U.S. FDA Accepts sNDA and Grants Priority Review to Bayer's Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer
WHIPPANY, N.J.--(BUSINESS WIRE)--Today Bayer announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and granted Priority Review ...
Bayer to sell cancer drug Stigvarga for up to $431M, WSJ reports
Bayer (BAYRY) has agreed to sell the rights to its cancer drug Stivarga to Gruenenthal Group for up to EUR 375M, or $431M, The Wall Street Journal’s Adria Calatayud reports.
Bayer Sells Cancer Drug to Gruenenthal for Up to $431 Million
The drug, approved to treat various forms of cancer, is due to lose patent protection in the EU in 2029 and in the U.S. a year later.
Robigo announces Series A funding led by Leaps by Bayer
Robigo announced a Series A funding led by Leaps by Bayer (BAYRY) with participation from Illumina Ventures, SVG Thrive, Congruent Ventures, and Endeavor8. The round will accelerate the commercial lau...
Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Robigo, a biotechnology company engineering no-compromise biological solutions for crop protection, today announced a Series A funding led by Leaps by Bayer with par...
Bayer receives FDA approval for Kerendia for CKD with type 1 diabetes
Bayer (BAYRY) announced that theFDA approved Kerendia to reduce urinary albumin-to-creatinine ratio, which is expected to reduce the risk of sustained estimated glomerular filtration rate decline and ...
Bayer's KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to reduce urinary albumin-to-creatinine ratio (UAC...
Bayer's Monsanto unit urges Missouri judge to approve $7.25 billion Roundup settlement
Bayer's Monsanto unit urged a Missouri judge on Monday to approve its $7.25 billion proposed settlement of lawsuits alleging that its weedkiller Roundup causes cancer, saying there is no other way to...
Bayer faces pivotal test of $7.25 billion Roundup settlement in Missouri court
Bayer's Monsanto unit heads to a Missouri state court on Monday seeking approval of a $7.25 billion settlement that could resolve tens of thousands of U.S. lawsuits alleging that its popular weedkill...
Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road
WHIPPANY, N.J.--(BUSINESS WIRE)--Amid growing concerns over misinformation around health and science, Bayer launched a nationwide tour of its Science Delivers mobile interactive experience. The mobile...
Bayer price target raised to EUR 65 from EUR 60 at HSBC
HSBC analyst Rajesh Kumar raised the firm’s price target on Bayer (BAYRY) to EUR 65 from EUR 60 and keeps a Buy rating on the shares. The firm adjusted targets…
Bayer granted accelerated approval for Hyrnuo by FDA
Bayer (BAYRY) announced that following Priority Review and Breakthrough Therapy Designation, the FDA has granted accelerated approval for Hyrnuo, for the first-line treatment of adult patients with lo...
U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
WHIPPANY, N.J.--(BUSINESS WIRE)--U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated NSCLC.
FDA grants accelerated approval to added indication for Bayer’s sevabertinib
The Food and Drug Administration granted accelerated approval to sevabertinib from Bayer (BAYRY) Healthcare Pharmaceuticals, a kinase inhibitor, for adult patients with locally advanced or metastatic ...
Bayer and Neste Close Commercial Agreement to Jointly Scale newgold® Winter Canola for Biofuels Production
MONHEIM, Germany & ST. LOUIS--(BUSINESS WIRE)--Bayer and Neste, the world's leading producer of renewable diesel and sustainable aviation fuel, have finalized a commercial agreement to jointly scale B...
Bayer initiates Phase II study of BAY 3670549 in patients with AFib
Bayer (BAYRY) announced the initiation of a global Phase II clinical trial evaluating BAY 3670549, an investigational highly selective G-protein-coupled inwardly rectifying potassium channel 4 inhibit...
BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the initiation of a global Phase II clinical trial (NCT07625215) evaluating BAY 3670549, an investigational highly selective G-protein-coupled in...
Bayer Crop Science Targets €3B Cash Flow by 2029 With Seeds-Led Growth
Bayer Aktiengesellschaft ETR: BAYN outlined progress on its Crop Science division's five-year framework at a 2026 innovation event in Iowa, reaffirming targets for above-market sales growth, a mid-20s...
Bayer Aktiengesellschaft Transcript: Investor update
A comprehensive update confirmed progress on the Five-Year Framework, with strong execution in margin expansion, cash productivity, and innovation-driven growth. Corn remains the main growth engine, while differentiated strategies across platforms and robust R&D underpin above-market growth and margin ambitions through 2029.
Bayer Aktiengesellschaft Press release: Investor update
Bayer Aktiengesellschaft issued a press release on September 2, 2026, disclosing material business information to investors.
Bayer Aktiengesellschaft Slides: Investor update
Bayer Aktiengesellschaft has posted slides in relation to its latest quarterly earnings report, which was published on September 2, 2026.
Bayer says Crop Science unit makes progress on product launches
Bayer said on Wednesday its Crop Science business had introduced two out of 10 planned new products with peak annual sales of at least €500 million ($579 million) each and mapped out further market...
Bayer Advances Combined Seed and Crop Protection Pipeline and Enters Phase of Blockbuster Launches
HUXLEY, Iowa--(BUSINESS WIRE)--Bayer is implementing its previously announced ambition to bring 10 blockbusters to market over 10 years, beginning to launch major Crop Science innovations in key agric...
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
Nearly a dozen drugmakers are reportedly slated to voluntarily sell their medications at lower prices under deals expected to be announced by President Donald Trump on Monday. The string of deals buil...